Milestone Pharmaceuticals (MIST) Price & Analysis

Compare

641 Followers

MIST Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.63 - $2.75

Previous CloseN/A

Volume143.50K

Average Volume (3M)1.08M

Market Cap

$167.44M

Enterprise Value$141.75M

Total Cash (Recent Filing)$43.42M

Total Debt (Recent Filing)$56.39M

Price to Earnings (P/E)―

Beta2.26

Next Earnings

Nov 12, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding84,994,260

10 Day Avg. Volume1,249,469

30 Day Avg. Volume1,077,489

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue1.31K

Enterprise Value/Gross Profit-5.45K

Enterprise Value/Ebitda-2.69

Forecast

1Y Price Target

$4.33

Price Target Upside123.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityMIST is expected to receive $75M in net proceeds upon approval from their RTW deal, which combined with proceeds from a recent financing, extends the cash runway into the first half of 2027.

Market PotentialThe planned US commercial launch indicates confidence in the product's market potential.

Regulatory ProcessThe FDA did not raise any concerns regarding the clinical package of the etripamil NDA, which is a positive indicator for approval.

Bears Say

Capital ConstraintsLaunch prospects are also constrained by limited capital.

Regulatory TimelineCardamyst has faced a longer regulatory timeline with prior Complete Response Letters and Refuse-to-file actions from the FDA, creating uncertainty about its approvability.

Milestone Pharmaceuticals News

Milestone Pharmaceuticals initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating and $4 price target The company...

8d ago

MIST

Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus

Milestone Pharmaceuticals ( ($MIST) ) has released its Q2 earnings. Here is a breakdown of the information Milestone...

1M ago

MIST

Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial Position

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals, with...

1M ago

MIST

Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost

The latest announcement is out from Milestone Pharmaceuticals ( ($MIST) ). Milestone Pharmaceuticals announced that the FDA has...

1M ago

MIST

Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)

“With the FDA’s recent acceptance of our response to the CRL, our team is energized as we work...

1M ago

MIST

Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Milestone Pharmaceuticals, with...

2M ago

MIST

Milestone Pharmaceuticals Announces Public Offering for $48.7M

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 11, 2025, Milestone Pharmaceuticals announced an underwritten...

2M ago

MIST

Why Is Milestone Pharmaceuticals Stock (MIST) Down 30% Today?

Milestone Pharmaceuticals stock was down on Friday after the company revealed plans for a public offering. ...

2M ago

MIST

Milestone prices $52.5M common shares offering at $1.50 per share

Milestone Pharmaceuticals (MIST) announced the pricing of its previously announced underwritten public offering of (i) 31.5M of its...

2M ago

MIST

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Investors will want to catch up on all of the hottest stock market news for Friday before signing off for the week. ...

2M ago

AMD

Milestone Pharmaceuticals Amends Royalty Agreement with RTW

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 10, 2025, Milestone Pharmaceuticals amended its Royalty...

2M ago

MIST

Milestone Pharmaceuticals commences underwritten public offering

Milestone Pharmaceuticals (MIST) has commenced an underwritten public offering of its common shares, accompanying Series A warrants to...

2M ago

MIST

Milestone announces FDA acceptance of response to CARDAMYST CRL

Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration has accepted for review Milestone’s response to...

2M ago

MIST

Milestone Pharmaceuticals’ Cardamyst Resubmission Boosts Buy Rating Amid Positive FDA Feedback and Market Potential

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Milestone Pharmaceuticals (MIST...

3M ago

MIST

MIST FAQ

What was Milestone Pharmaceuticals’s price range in the past 12 months?

Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $2.75 in the past 12 months.

What is Milestone Pharmaceuticals’s market cap?

Milestone Pharmaceuticals’s market cap is $167.44M.

When is Milestone Pharmaceuticals’s upcoming earnings report date?

Milestone Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 54 days.

How were Milestone Pharmaceuticals’s earnings last quarter?

Milestone Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.

Is Milestone Pharmaceuticals overvalued?

According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Milestone Pharmaceuticals pay dividends?

Milestone Pharmaceuticals does not currently pay dividends.

What is Milestone Pharmaceuticals’s EPS estimate?

Milestone Pharmaceuticals’s EPS estimate is -0.16.

How many shares outstanding does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals has 84,994,260 shares outstanding.

What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?

Milestone Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went up 7.097%.

Which hedge fund is a major shareholder of Milestone Pharmaceuticals?

Currently, no hedge funds are holding shares in MIST

Milestone Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-780.29%

Trailing 12-Months

Asset Growth

-46.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals (MIST) Earnings & Revenues

Historic Earnings Reports

MIST Stock 12 Month Forecast

Average Price Target

$4.33

▲(123.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.083076923076923,2.3261538461538462,2.5692307692307694,2.8123076923076926,3.0553846153846154,3.2984615384615386,3.5415384615384617,3.7846153846153845,4.027692307692308,4.270769230769231,4.513846153846154,4.756923076923077,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.0315384615384615,2.223076923076923,2.414615384615385,2.6061538461538465,2.7976923076923077,2.9892307692307694,3.180769230769231,3.3723076923076922,3.5638461538461543,3.7553846153846155,3.9469230769230768,4.138461538461539,{"y":4.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.0061538461538464,2.1723076923076925,2.3384615384615386,2.5046153846153847,2.670769230769231,2.836923076923077,3.0030769230769234,3.1692307692307695,3.3353846153846156,3.5015384615384617,3.667692307692308,3.833846153846154,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >